Results 71 to 80 of about 21,140 (245)

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis

open access: yesBMC Medicine, 2019
Background Naltrexone is an opioid antagonist used in many different conditions, both licensed and unlicensed. It is used at widely varying doses from 3 to 250 mg.
Monica Bolton   +7 more
doaj   +1 more source

ERNEST COST action overview on the (patho)physiology of GPCRs and orphan GPCRs in the nervous system

open access: yesBritish Journal of Pharmacology, EarlyView.
G protein‐coupled receptors (GPCRs) are a large family of cell surface receptors that play a critical role in nervous system function by transmitting signals between cells and their environment. They are involved in many, if not all, nervous system processes, and their dysfunction has been linked to various neurological disorders representing important
Necla Birgül Iyison   +15 more
wiley   +1 more source

Cannabidiol dose dependently reduces alcohol intake in mice via a non‐5‐HT1A receptor mechanism: Exploration of other potential receptor targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Binge drinking is a risky pattern of alcohol intake and a major predictor of alcohol use disorder (AUD). Current AUD medications have limited efficacy and poor patient compliance, calling for more effective therapeutics.
Connie J. Badolato   +4 more
wiley   +1 more source

A GLP‐1R/Y1 receptor/Y2 receptor triple agonist decreases fentanyl‐evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Emerging literature indicates that simultaneously targeting glucagon‐like peptide‐1 receptors (GLP‐1Rs) and neuropeptide Y receptors (Y1/Y2) may represent a new pharmacotherapeutic approach to treating opioid use disorder (OUD).
Antonia Caffrey   +5 more
wiley   +1 more source

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients

open access: yesJournal of Translational Medicine, 2018
Background Around 30% of patients with inflammatory bowel disease (IBD) are refractory to current IBD drugs or relapse over time. Novel treatments are called for, and low dose Naltrexone (LDN) may provide a safe, easily accessible alternative treatment ...
Mitchell R. K. L. Lie   +6 more
doaj   +1 more source

Opioid receptors in cardiovascular function

open access: yesBritish Journal of Pharmacology, EarlyView.
Opioid receptors are G protein‐coupled receptors expressed by various cells in the heart, including myocytes and nerve fibres, and play a crucial role in modulating cardiac function. These receptors influence neural transmission, heart rate and myocyte contractility, offering cardioprotection.
Venkatesh Katari   +4 more
wiley   +1 more source

Open Label Trial of Naltrexone Implants: Measuring Blood Serum Levels of Naltrexone

open access: yesSubstance Abuse: Research and Treatment, 2013
The usefulness of oral naltrexone has been limited by compliance. Sub-cutaneous implants would seem to offer a solution to this problem and improve long-term outcomes.
Ross M. Colquhoun
doaj   +1 more source

Stabilization of remission in patients with opioid depen dence: pharmacological and pharmacogenetic aspects

open access: yesУчёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2016
Modern narcology demonstrates a problem of insufficient effectiveness of pharmacotherapy for stabilization of remission in patients with opioid dependence.
V. Ya. Palatkin   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy